Mercados españoles cerrados

DexCom, Inc. (DC4.DE)

XETRA - XETRA Precio demorado. Divisa en EUR
Añadir a la lista de favoritos
121,16+0,68 (+0,56%)
Al cierre: 05:35PM CEST

DexCom, Inc.

6340 Sequence Drive
San Diego, CA 92121
United States
858 200 0200
https://www.dexcom.com

Sector(es)Healthcare
SectorMedical Devices
Empleados a tiempo completo9500

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Kevin Ronald SayerExecutive Chairman, CEO & President2,97MN/A1958
Mr. Jereme M. SylvainExecutive VP, CFO & Chief Accounting Officer1,04MN/A1980
Mr. Jacob Steven LeachExecutive VP & COO1,19MN/A1978
Mr. Michael Jon BrownExecutive VP & Chief Legal Officer1,12MN/A1970
Ms. Teri LawverExecutive VP & Chief Commercial Officer1,3MN/A1967
Mr. Girish NaganathanExecutive VP & CTO390,08kN/A1977
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Gobierno corporativo

El ISS Governance QualityScore de DexCom, Inc., a día 1 de mayo de 2024, es 5. Las puntuaciones base son Auditoría: 2; Tablero: 9; Derechos de los accionistas: 6; Compensación: 2.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.